• ColoSTAT blood-based colorectal cancer test accredited by NATA
• Accreditation confirms test meets highest international standards
• Enables commercial launch of ColoSTAT testing services in Australia

Rhythm Biosciences Ltd has announced that the National Association of Testing Authorities (NATA) has confirmed successful completion of the variation-to-scope assessment for the company's ColoSTAT blood-based colorectal cancer test. Following this assessment, ColoSTAT is now included within the accredited scope of Rhythm's ISO 15189:2022 laboratory in Parkville, Victoria. This milestone formally recognises ColoSTAT as an accredited clinical laboratory service, confirming that the laboratory and test method meet internationally recognised standards for quality, competence, and traceability under the ISO 15189:2022 standard. NATA accreditation reflects the independent assurance that Rhythm's laboratory systems and the technical performance of ColoSTAT meet the globally recognised clinical laboratory standard. The inclusion of ColoSTAT as an accredited clinical service enables Rhythm to commence offering the test to referring clinicians and patients in Australia as part of the company's commercial launch strategy. Rhythm intends to progressively expand clinician awareness and referral pathways as part of the rollout of ColoSTAT testing services in the Australian market. NATA accreditation represents an important prerequisite for engagement with the Medical Services Advisory Committee (MSAC) regarding a potential Medicare Benefits Schedule (MBS) listing, which would support broader clinical adoption of ColoSTAT within Australia's healthcare system.

The company will provide further updates as it progresses the commercial rollout of ColoSTAT.